MARTIN J. KENDALL, M.D.; DAVID B. JACK, PH.D.
To the editor: We agree with the authors of "Under-representation of Women in New Drug Trials" (1) that the understandable tendency to exclude female subjects from pharmacokinetic studies and early clinical trials means that many drugs are incompletely evaluated before marketing. Thereafter, unless specific restrictions are imposed, the drug may be taken by as many women as men and the assumption is often made that the pharmacokinetic data previously obtained will be equally applicable to members of both sexes.
Because any new drug has to be considered to have potential teratogenic effects, it would be immoral to expose a potentially
KENDALL MJ, JACK DB. Women in New Drug Trials. Ann Intern Med. ;96:376–377. doi: 10.7326/0003-4819-96-3-376_2
Download citation file:
Published: Ann Intern Med. 1982;96(3):376-377.
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use